Back to results

Hydrogel Patch for the Treatment of Eczema

Primary Purpose

Eczema

Status

Terminated

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

hydrogel patch

Triamcinolone (TAC) 0.1% cream

About this trial

This is an interventional treatment trial for Eczema focused on measuring eczema, at least 3 patches of eczema

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subject has signed the informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization form;
Male or female subject at least 12 years of age; subjects under 18 years of age will need parental or official guardian consent.
A diagnosis of eczema with at least three lesions no larger than 7 by 7 cm on either the trunk, arms, or legs that would serve as target lesions. The lesions must be wide enough apart so that there is no overlap of hydrogel patches. All three lesions must have at least 5 out of 12 points on the modified EASI scale. Each of the three lesions must have no greater than 1 point difference from each other on the modified EASI score. (If the subject can identify specific eczema lesions that are more pruritic, recalcitrant and/or tend to initiate the itch-scratch cycle, then those lesions will be preferentially selected as the target lesions.)
Any additional diagnoses must, in the investigator's opinion, not preclude the subject from safely participating in this study or interfere with the evaluation of the subject's eczema;
Subject is able to completely discontinue the use of any medication or therapy (other than study medications) for relief of eczema in the target areas to be treated;
Subject is able to completely discontinue the use of any systemic medication or therapy (e.g. oral medications, phototherapy, herbal remedies, or acupuncture) for relief of eczema;
Subject must be reliable and mentally competent to complete study measurements;
Subject is able to understand and agrees to comply with study requirements, attend study visits, and comply with the restrictions during the study.

Exclusion Criteria:

Subjects with exclusively hand, face, foot, and/or groin dermatitis
Known hypersensitivity to any component of the test medications;
Pigmentation, extensive scarring, or pigmented lesions in affected areas that would interfere with evaluation of efficacy parameters;
Clinically infected eczema at baseline.
Any evidence of atrophy in the areas selected for treatment with topical corticosteroid;
Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. oral corticosteroids, immunosuppressants, antibiotics, sedating antihistamines). Inhaled steroids will be permitted.
Topical therapies (other than non-prescription emollients) on potential target lesions within one week of starting study treatment;
Systemic therapy, phototherapy, or a systemic investigational therapy for eczema within 30 days prior to study entry;
Subject is considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators.

Sites / Locations

UCSF Psoriasis Skin and Treatment Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Patch + cream, patch alone, cream alone

Arm Description

This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.

Outcomes

Primary Outcome Measures

Change in Disease Severity: Percent Change in Mean EASI Score

Percent change in mean EASI score week 0 to week 6: Each lesion was scored using a 12-point modified Eczema Area and Severity Index (EASI) at baseline and 2 weeks after the 4-week treatment period (week6). An experienced evaluator assessed each lesion on the severity of 4 domains, with higher scores indicating more severity: 1) intensity of redness (erythema), 2) thickness (induration, papulation, oedema), 3) scratching (excoriation) and 4) lichenification (lined skin) as as none (0), mild (1), moderate (2) and severe (3). Pictorial and descriptive instructions guided the evaluator in scoring the lesions based on visual appearance.

Secondary Outcome Measures

Number of Adverse Events Associated With Treatment

Full Information

NCT ID

NCT00924508

First Posted

June 17, 2009

Last Updated

December 30, 2013

Sponsor

University of California, San Francisco

Collaborators

Teikoku Pharma USA, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT00924508

Brief Title

Hydrogel Patch for the Treatment of Eczema

Official Title

A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema

Study Type

Interventional

2. Study Status

Record Verification Date

December 2013

Overall Recruitment Status

Terminated

Why Stopped

Loss of Funding

Study Start Date

July 2008 (undefined)

Primary Completion Date

September 2011 (Actual)

Study Completion Date

July 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

University of California, San Francisco

Collaborators

Teikoku Pharma USA, Inc.

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The primary objective of this clinical study is to determine whether occlusion of triamcinolone 0.1% cream (TAC) with hydrogel patch improves its efficacy in treating eczema. A secondary objective is to determine whether eczema improves under occlusion with hydrogel patch alone, without TAC.

Detailed Description

This will be a 6-week, open label, bilaterally-controlled single center study involving 30 subjects age 13 and older with eczema. The primary objective of this clinical study is to determine whether occlusion of triamcinolone 0.1% cream (TAC) used to treat eczema with hydrogel patch improves its efficacy. A secondary objective is to determine whether eczema improves under occlusion with hydrogel patch alone. All subjects will have 3 target lesions of similar severity followed throughout the study. Patients will apply hydrogel patch alone to the first lesion, TAC 0.1% cream to the second lesion, and TAC 0.1% cream occluded by hydrogel patch to the third lesion. All treatments are twice a day for a maximum of 4 weeks or until lesions are cleared. The modified Eczema Area and Severity Index (EASI) score will be used to evaluate each lesion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Eczema

Keywords

eczema, at least 3 patches of eczema

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

23 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Patch + cream, patch alone, cream alone

Arm Type

Experimental

Arm Description

Intervention Type

Device

Intervention Name(s)

hydrogel patch

Other Intervention Name(s)

Occlusion, Patch, Hydrogel

Intervention Description

occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.

Intervention Type

Drug

Intervention Name(s)

Triamcinolone (TAC) 0.1% cream

Other Intervention Name(s)

Triamcinolone Acetonide cream, TAC cream [United States Pharmacopeia, (USP), 0.1%]

Intervention Description

Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.

Primary Outcome Measure Information:

Title

Change in Disease Severity: Percent Change in Mean EASI Score

Description

Time Frame

Baseline, 6 weeks

Secondary Outcome Measure Information:

Title

Number of Adverse Events Associated With Treatment

Time Frame

6 weeks

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Subject has signed the informed consent form and Health Insurance Portability and Accountability Act (HIPAA) authorization form; Male or female subject at least 12 years of age; subjects under 18 years of age will need parental or official guardian consent. A diagnosis of eczema with at least three lesions no larger than 7 by 7 cm on either the trunk, arms, or legs that would serve as target lesions. The lesions must be wide enough apart so that there is no overlap of hydrogel patches. All three lesions must have at least 5 out of 12 points on the modified EASI scale. Each of the three lesions must have no greater than 1 point difference from each other on the modified EASI score. (If the subject can identify specific eczema lesions that are more pruritic, recalcitrant and/or tend to initiate the itch-scratch cycle, then those lesions will be preferentially selected as the target lesions.) Any additional diagnoses must, in the investigator's opinion, not preclude the subject from safely participating in this study or interfere with the evaluation of the subject's eczema; Subject is able to completely discontinue the use of any medication or therapy (other than study medications) for relief of eczema in the target areas to be treated; Subject is able to completely discontinue the use of any systemic medication or therapy (e.g. oral medications, phototherapy, herbal remedies, or acupuncture) for relief of eczema; Subject must be reliable and mentally competent to complete study measurements; Subject is able to understand and agrees to comply with study requirements, attend study visits, and comply with the restrictions during the study. Exclusion Criteria: Subjects with exclusively hand, face, foot, and/or groin dermatitis Known hypersensitivity to any component of the test medications; Pigmentation, extensive scarring, or pigmented lesions in affected areas that would interfere with evaluation of efficacy parameters; Clinically infected eczema at baseline. Any evidence of atrophy in the areas selected for treatment with topical corticosteroid; Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period (e.g. oral corticosteroids, immunosuppressants, antibiotics, sedating antihistamines). Inhaled steroids will be permitted. Topical therapies (other than non-prescription emollients) on potential target lesions within one week of starting study treatment; Systemic therapy, phototherapy, or a systemic investigational therapy for eczema within 30 days prior to study entry; Subject is considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

John Koo, MD

Organizational Affiliation

University of California, San Francisco

Official's Role

Principal Investigator

Facility Information:

Facility Name

UCSF Psoriasis Skin and Treatment Center

City

San Francisco

State/Province

California

ZIP/Postal Code

94118

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Hydrogel Patch for the Treatment of Eczema

We'll reach out to this number within 24 hrs